Please login to the form below

Not currently logged in
Email:
Password:

Ono

This page shows the latest Ono news and features for those working in and with pharma, biotech and healthcare.

Research charity LifeArc cashes $1.2bn royalty from Keytruda

Research charity LifeArc cashes $1.2bn royalty from Keytruda

In March it formed a cancer immunotherapy alliance with CRUK and Ono Pharma, in April it licensed an ion channel drug discovery programme to Daiichi Sankyo, and in early May it

Latest news

  • BMS adds another Ono drug to its immuno-oncology portfolio BMS adds another Ono drug to its immuno-oncology portfolio

    It will collaborate with Ono in developing the drug in Japan, South Korea and Taiwan. ... Ono’s prostaglandin E2 receptor antagonist programmes offer the potential to develop targeted therapies that counteract the effects of an immunosuppressive tumour

  • Merck settles PD-1 patent lawsuit with BMS and Ono Merck settles PD-1 patent lawsuit with BMS and Ono

    The initial payment and royalties will be shared between Ono and BMS with the Japanese firm getting a quarter share and BMS pocketing the remainder. ... BMS and Ono were first to market with their Opdivo (nivolumab) PD-1 inhibitor, claiming approval in

  • Ono faces steep price cut for Opdivo in Japan Ono faces steep price cut for Opdivo in Japan

    Japan has followed through on plans for an out-of-cycle price cut for Ono Pharmaceuticals' cancer drug Opdivo, lowering it by 50%. ... Ono has said it is considering filing an objection to the decision, on the grounds that the move will disrupt its

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    Ono Pharmaceutical was also developing a drug in the class called ONO-5334 but pulled the programme in 2012 without giving reasons for the decision, while Medivir discontinued its MIV 701

  • Immunotherapy and future directions in oncology Immunotherapy and future directions in oncology

    To date, three immune checkpoint inhibitors reached the market: ipilimumab (Yervoy, Bristol-Myers Squibb), nivolumab (Opdivo, Bristol-Myers Squibb and Ono Pharmaceuticals), and pembrolizumab (Keytruda, Merck &Co.) - all three marketed for

More from news
Approximately 7 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Clearly on a roll with Japan, X-Chem has also signed a deal with Ono Pharmaceutical covering oncology targets.

  • Deal Watch January 2017 Deal Watch January 2017

    If the old year goes out like a lion, the New Year will come in like a lamb This month saw BMS/Ono reach an agreement with Merck &Co in their ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Deal Watch July 2016 Deal Watch July 2016

    In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments. In this collaboration the focus is

  • Pharma deals during August 2013 Pharma deals during August 2013

    Onyx has sole marketing rights with the exception of Japan where it is licensed to Ono Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics